No Place to Call Home — Policies to Reduce ED use in Medicaid by Friedman, Ari B
University of Pennsylvania
ScholarlyCommons
Health Care Management Papers Wharton Faculty Research
6-18-2015
No Place to Call Home — Policies to Reduce ED
use in Medicaid
Ari B. Friedman
University of Pennsylvania
Follow this and additional works at: http://repository.upenn.edu/hcmg_papers
Part of the Health and Medical Administration Commons, and the Health Services Research
Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/hcmg_papers/61
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Friedman, A. B. (2015). No Place to Call Home — Policies to Reduce ED use in Medicaid. The New England Journal of Medicine, 372
(25), 2382-2385. http://dx.doi.org/10.1056/NEJMp1502627
No Place to Call Home — Policies to Reduce ED use in Medicaid
Keywords
medicare, medicaid, health care, emergency medicine
Disciplines
Health and Medical Administration | Health Services Research
This journal article is available at ScholarlyCommons: http://repository.upenn.edu/hcmg_papers/61
PERSPECTIVE
n engl j med 372;25 nejm.org june 18, 20152382
tion are likely to reduce the mar-
ket penetration of interchange-
able biologics.
The challenges to achieving 
savings from follow-on biologics 
are large but not insurmount-
able. First, market-entry hurdles 
should be low enough to ensure 
that enough companies compete 
to affect prices. Public investment 
in technological advances that 
can support biosimilar develop-
ment, such as advancing knowl-
edge about glycosylating human 
proteins in yeast, can aid all 
manufacturers. The 
FDA can help by 
promulgating prod-
uct-specific guid-
ance on how companies can 
demonstrate biosimilarity or in-
terchangeability, to reduce the 
disadvantages for the first compa-
nies to try. Legislators may also 
need to reexamine the process 
for exchanging information about 
 potentially infringing patents, to 
ensure that innovator manufac-
turers cannot unreasonably delay 
the process in order to extend 
their market exclusivity, and to 
prevent biosimilar manufactur-
ers from entering into anticom-
petitive settlements. Such settle-
ments have bedeviled the generic 
small-molecule drug industry but, 
since 2003, have had to be re-
ported to the Federal Trade 
Commission for evaluation of 
their anticompetitive effects. This 
requirement may have to be ex-
tended to biologic drugs.
Innovative approaches will be 
required to ensure mandatory, 
rigorous postapproval research 
on the safety and effectiveness of 
biosimilars compared with their 
innovator predecessors in order 
to promote confidence in these 
new products. Over the long term, 
attention to both these areas will 
help ensure that U.S. patients ben-
efit from appropriate price reduc-
tions for older biologic drugs 
that are essential for their clini-
cal care. At the same time, fair 
but appropriately limited peri-
ods of exclusivity will reward 
the innovators of the original 
products while also spurring them 
to create new products rather 
than prolong exclusivity rights 
over older ones long after such 
monopolies should have come to 
a natural end.
Disclosure forms provided by the authors 
are available with the full text of this article 
at NEJM.org.
From the Program on Regulation, Thera-
peutics, and Law (PORTAL), Division of 
Pharmacoepidemiology and Pharmacoeco-
nomics, Department of Medicine, Brigham 
and Women’s Hospital and Harvard Medi-
cal School, Boston.
This article was published on May 6, 2015, 
at NEJM.org.
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No Place to Call Home — Policies to Reduce ED Use  
in Medicaid
Ari B. Friedman, M.S., Brendan Saloner, Ph.D., and Renee Y. Hsia, M.D.
One goal of Medicaid expan-sion under the Affordable 
Care Act (ACA) is to provide low-
income, medically vulnerable 
adults with a source of care out-
side the emergency department 
(ED) and the means to pay for 
that care. Yet Medicaid expan-
sion alone may not reduce ED 
use among new enrollees. Al-
though some research suggests 
that Medicaid coverage is asso-
ciated with reduced ED use, a 
lottery-based, controlled study 
from Oregon found that newly 
enrolled beneficiaries actually 
increased their ED use, at least 
temporarily.1 This finding is not 
surprising, since health insur-
ance reduces financial barriers 
to being seen promptly, and the 
            An audio interview 
with Dr. Kesselheim 
is available at NEJM.org 
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newly enrolled Medicaid popula-
tion has pent-up demand for care 
and a high burden of chronic 
disease. Although the contribu-
tion of ED use to cost growth is 
sometimes exaggerated, it remains 
a substantial source of health 
care costs, representing at least 
5 to 6% of U.S. health expendi-
tures.2 Medicaid alone spends 
$23 billion to $47 billion annu-
ally on ED care,2 and some of the 
sickest Medicaid enrollees are 
seen in the ED.
Broadly speaking, two ap-
proaches have been proposed for 
reducing use of the ED in this 
population. One focuses on mak-
ing the ED more costly for pa-
tients to use; the other, on creat-
ing more robust alternatives to the 
ED. Although not incompatible, 
these approaches reflect different 
beliefs about why Medicaid bene-
ficiaries use the ED for medical 
issues that could potentially be 
addressed elsewhere.
By imposing steep copayments 
for certain ED visits, the first ap-
proach aims to place responsibil-
ity on beneficiaries to make vigi-
lant choices about when medical 
issues require emergency atten-
tion (see graph for reasons pa-
tients visit the ED). For instance, 
as part of its ACA Medicaid ex-
pansion, Indiana was granted 
permission by the Centers for 
Medicare and Medicaid Services 
(CMS) to undertake a demonstra-
tion project involving charging 
Medicaid recipients — many of 
whom have family incomes be-
low the federal poverty level — 
$8 for their first visit to the ED 
and $25 for subsequent visits 
during the same year. The copay-
ment applies when the visit is de-
termined to be for “non-
emergency” care, the patient did 
not receive prior authorization 
from his or her managed-care 
organization, or the emergency 
provider informed the patient that 
the problem could be managed 
in another setting.
The logic behind increasing 
cost sharing for “nonemergency” 
ED visits is that it will motivate 
patients to use lower-cost care 
sites for most conditions, reserv-
ing the ED for times when they 
truly need immediate attention. 
This simple narrative, however, 
is challenged by research. States 
have had the option since 2005 
of imposing copayments for Med-
icaid beneficiaries of up to $15 
for nonemergency ED use, yet 
the eight states that implemented 
these programs saw no reduction 
in ED visits by Medicaid recipi-
ents relative to other states.3
Case studies of Medicaid cost 
sharing in other contexts simi-
larly found that copayments 
alone do not reduce ED visits for 
diseases that can safely be treat-
ed in primary care settings. Analy-
ses that have shown associations 
between copayments and reduc-
tions in “unnecessary” ED use 
are limited by their use of diag-
nosis or triage codes to deter-
mine retrospectively whether a 
visit qualifies as “nonurgent.”
One explanation for these 
findings is that even informed 
patients cannot necessarily trans-
late their symptoms and history 
into a diagnosis, much less a 
prognosis. Patients present to the 
ED with symptoms that may sig-
nal an emergency, such as chest 
pain, and clinicians are able to 
rule out an emergency only after 
performing an evaluation and di-
agnostic tests. Indeed, 88% of all 
visits that are retrospectively de-
termined to be for “nonemer-
gency” (primary care treatable) di-
agnoses cannot be distinguished 
from true emergencies at the 
time of admission on the basis of 
the patient’s chief complaint.4 It 
Reasons for Visiting the Emergency Department.
Data are from the National Health Interview Survey 2011–2013. Respondents could select more 
than one answer. The sample is nonelderly adults (18 to 64 years of age) who have had an emer-
gency department visit in the 12 months before they were interviewed. Persons who were known 
to have been uninsured in the previous 12 months are excluded from the Private and Medicaid 
categories. 
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is neither ethical nor prudent for 
clinicians to withhold care until 
they can determine whether a 
case is an emergency — and at 
that point opportunities for cost 
savings through diversion from 
the ED would probably be 
 minimal.
Instead of requiring Medicaid 
patients to pay for a portion of 
their ED care, some states are 
trying to provide them with bet-
ter alternatives to the ED. This 
strategy requires that beneficia-
ries have access to a primary 
care provider who can help pre-
vent exacerbations of chronic ill-
nesses such as asthma that might 
otherwise lead to acute crises. 
Well-managed systems can also 
provide prompt appointments to 
patients with time-sensitive health 
concerns that are not necessarily 
emergencies — such as a persis-
tent, moderate headache that 
does not get better with over-the-
counter medications.
At the core of this alternative 
approach to reducing ED visits are 
key components of the patient-
centered medical home model, 
including care coordination, case 
management, extended hours, 
and walk-in visits. Medical-home 
initiatives emphasize prevention 
and post-acute care, and prelimi-
nary studies have shown these 
models to be effective in reduc-
ing ED use among Medicaid ben-
eficiaries.5 The ACA includes an 
optional program that gives states 
additional funding to support 
providers that develop “health 
homes” for Medicaid beneficia-
ries with multiple chronic physi-
cal conditions or severe mental 
illness. The program has been 
adopted by 16 states to date. Suc-
cessful utilization of medical-
home initiatives to reduce ED 
visits will depend on access to 
providers who are willing to take 
Medicaid patients. Among other 
things, this approach will require 
the establishment of new access 
points for Medicaid beneficiaries 
through the growth of commu-
nity health centers; policies that 
increase physician participation 
in Medicaid, such as reimburse-
ment at parity with Medicare 
rates; and better support for par-
ticipating practices, ranging from 
financial incentives for providing 
after-hours coverage, to shared 
electronic health records, to inte-
grated behavioral health services.
Medical homes can be aug-
mented with other resources to 
improve ease of use. For exam-
ple, transportation is a common 
barrier to receiving timely pri-
mary care for low-income pa-
tients, yet ironically states such 
as Indiana that are seeking to 
penalize patients for ED use have 
used the same waiver process to 
curtail nonemergency transporta-
tion. Facilitating access to non-
emergency transportation — for 
instance, by providing patients 
with taxi vouchers, subway to-
kens, or paratransit access — is 
critical, given that many Medic-
aid beneficiaries live in commu-
nities that lack such accessible 
options as retail or urgent care 
clinics.
Additional resources are also 
needed for triaging patients’ 
health concerns and providing 
care in alternative settings. Policy-
makers may look beyond the 
United States for promising 
models. France, for instance, tri-
ages callers to its “15” line (the 
medical portion of its 911-equiv-
alent) to a lay dispatcher or an 
on-call physician who can pro-
vide medical advice over the phone. 
If medical advice is insufficient, 
the dispatcher can advise the pa-
tient to see his or her primary 
care physician or can dispatch a 
physician to deliver care in the 
patient’s home or send an ambu-
lance. Differences in health sys-
tem financing between the two 
countries would make it difficult 
to adopt this triage system whole-
sale in the United States. But 
state Medicaid programs could 
create financial incentives for 
Medicaid managed-care organi-
zations to provide a help line to 
assist patients in choosing ap-
propriate treatments and venues.
ED waiting rooms impose a 
substantial time cost on people 
seeking care, yet more patients 
visit the ED every year. Burden-
ing patients with a bill if the 
cause of their visit is retroactive-
ly deemed not to have been an 
emergency will probably prove 
neither equitable nor effective in 
directing patients to alternative 
settings and could lead to unin-
tended consequences if patients 
avoid care out of fear of econom-
ic hardship. Given these ramifi-
cations and the ineffectiveness 
of past attempts to impose costs 
on Medicaid patients seeking ED 
care, the Obama administration’s 
decision to approve demonstra-
tion projects involving high cost 
sharing and loss of transporta-
tion coverage is troubling. In-
stead, CMS might encourage 
state initiatives to develop robust 
ED alternatives. Although this ap-
proach requires more substantial 
changes to the health care system, 
it may be one of the most mean-
ingful and sustained ways to 
improve the care of all medically 
or financially vulnerable Ameri-
cans, especially Medicaid bene-
ficiaries.
Disclosure forms provided by the authors 
are available with the full text of this article 
at NEJM.org.
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